PubMed Health⌕ Search

Biomedical subjects

P E Bergner

Publications and source records attributed to P E Bergner.

11 recordsLinked to original sources
PubMed1978

Evaluation of a slow-release lithium carbonate formulation.

A slow-release lithium preparation was compared with a standard formulation in normal volunteers and in patients. Pharmacokinetic parameters of normal volunteers were examined after a single dose of each form and the steady-state levels after a b.i.d. dose of the slow-release form. These initial single-dose data suggested that the two formulations are not bioequivalent. However, the area under the curve of the two forms was similar, and the essentially complete recovery of lithium from urine in steady state indicates equal bioavailability. The patients' steady-state levels for the two formulations essentially confirmed the normal subjects' data: with the slow-release form plasma lithium levels were slightly higher, and the postdose lithium level variability was decreased by as much as 50%.

Biological Availability↗
PubMed1975

Butaperazine pharmacokinetics. Effect of dosage regimen on steady state blood levels.

Experimental evidence showed that a higher whole blood steady state drug plasma level was achieved when a patient was given medication three times a day compared to the same total daily dose once a day. In addition, evidence indicated possible enzyme induction by butaperazine in one patient. We have demonstrated that the general stochastic theory developed to investigate the pharmacokinetics of lithium carbonate "in vivo" has more general applicability in that it applies also to butaperazine, and facilitates interpretation of findings (without blood level data) in one other drug study.

Administration, Oral↗
PubMed1973

Lithium kinetics in man: effect of variation in dosage pattern.

1. Utilizing a general stochastic theory of drug kinetics we have demonstrated that from the serum concentration curve derived from a single dose of lithium, it is possible to predict the steady state concentration, the time required to reach steady state, the dependency of these quantities on the time interval between drug administrations and the fluctuations in plasma level under steady state conditions.2. It has been shown in general that the more frequently the drug is administered the higher is the steady state level, the shorter is the time required to reach steady state, and the smaller are the fluctuations.

Biopharmaceutics↗